153 related articles for article (PubMed ID: 8976818)
1. Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro.
Dorr RT; Lagel K; McLean S
Eur J Cancer; 1996; 32A Suppl 4():S21-5. PubMed ID: 8976818
[TBL] [Abstract][Full Text] [Related]
2. Cytoprotective agents for anthracyclines.
Dorr RT
Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
[TBL] [Abstract][Full Text] [Related]
3. Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity.
Nazeyrollas P; Prévost A; Baccard N; Manot L; Devillier P; Millart H
Cancer Chemother Pharmacol; 1999; 43(3):227-32. PubMed ID: 9923553
[TBL] [Abstract][Full Text] [Related]
4. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR
Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777
[TBL] [Abstract][Full Text] [Related]
5. Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC).
Khodarev NN; Kataoka Y; Murley JS; Weichselbaum RR; Grdina DJ
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):553-63. PubMed ID: 15380592
[TBL] [Abstract][Full Text] [Related]
6. WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells.
Alberts DS; Speicher LA; Krutzsch M; Wymer J; Capizzi RL; Conlon J; Barrett A; Aickin M
Eur J Cancer; 1996; 32A Suppl 4():S17-20. PubMed ID: 8976817
[TBL] [Abstract][Full Text] [Related]
7. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
Shaw LM; Bonner HS; Brown DQ
Drug Metab Dispos; 1994; 22(6):895-902. PubMed ID: 7895607
[TBL] [Abstract][Full Text] [Related]
8. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines.
Merlin JL; Marchal S; Ramacci C; Berlion M; Poullain MG
Anticancer Drugs; 2002 Feb; 13(2):141-7. PubMed ID: 11901306
[TBL] [Abstract][Full Text] [Related]
10. Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro.
Fulda S; Oster W; Berthold F
Anticancer Drugs; 1997 Jan; 8(1):34-41. PubMed ID: 9147609
[TBL] [Abstract][Full Text] [Related]
11. Amifostine does not inhibit the toxic effects of anthracycline derivates or mitoxantrone on MDR tumor cell lines.
Michieli M; Michelutti A; Damiani D; Ermacora A; Masolini P; Stocchi R; Russo D
Leuk Lymphoma; 2001 Aug; 42(4):721-9. PubMed ID: 11697502
[TBL] [Abstract][Full Text] [Related]
12. Amifostine protects against early but not late toxic effects of doxorubicin in infant rats.
Jahnukainen K; Jahnukainen T; Salmi TT; Svechnikov K; Eksborg S; Söder O
Cancer Res; 2001 Sep; 61(17):6423-7. PubMed ID: 11522636
[TBL] [Abstract][Full Text] [Related]
13. The radioprotective agent, amifostine, suppresses the reactivity of intralysosomal iron.
Yu Z; Eaton JW; Persson HL
Redox Rep; 2003; 8(6):347-55. PubMed ID: 14980067
[TBL] [Abstract][Full Text] [Related]
14. Hypotensive mechanisms of amifostine.
Ryan SV; Carrithers SL; Parkinson SJ; Skurk C; Nuss C; Pooler PM; Owen CS; Lefer AM; Waldman SA
J Clin Pharmacol; 1996 Apr; 36(4):365-73. PubMed ID: 8728352
[TBL] [Abstract][Full Text] [Related]
15. Selective exclusion by the polyamine transporter as a mechanism for differential radioprotection of amifostine derivatives.
Quiñones HI; List AF; Gerner EW
Clin Cancer Res; 2002 May; 8(5):1295-300. PubMed ID: 12006551
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of some latent radioprotective compounds.
Vos O; Budke L; Grant GA
Int J Radiat Biol Relat Stud Phys Chem Med; 1976 Nov; 30(5):433-48. PubMed ID: 187547
[TBL] [Abstract][Full Text] [Related]
17. Manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by the free thiol form of amifostine and tumor necrosis factor alpha.
Murley JS; Kataoka Y; Baker KL; Diamond AM; Morgan WF; Grdina DJ
Radiat Res; 2007 Apr; 167(4):465-74. PubMed ID: 17388698
[TBL] [Abstract][Full Text] [Related]
18. Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
Levi M; DeRemer SJ; Dou C; Ensminger WD; Smith DE
Biopharm Drug Dispos; 2004 Jan; 25(1):27-35. PubMed ID: 14716750
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Herman EH; Zhang J; Chadwick DP; Ferrans VJ
Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
[TBL] [Abstract][Full Text] [Related]
20. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity.
List AF; Heaton R; Glinsmann-Gibson B; Capizzi RL
Semin Oncol; 1996 Aug; 23(4 Suppl 8):58-63. PubMed ID: 8783669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]